Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.16
  • Today's Change0.17 / 5.69%
  • Shares traded37.19k
  • 1 Year change+46.30%
  • Beta0.8969
Data delayed at least 15 minutes, as of May 03 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.

  • Revenue in EUR (TTM)17.48m
  • Net income in EUR-110.43m
  • Incorporated2011
  • Employees112.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
AB Science SA777.00k-16.89m102.58m89.00------132.02-0.3561-0.35610.0164-0.38790.02840.3942.507,471.15-61.64-70.81-237.22-316.6388.1691.37-2,173.10-1,225.491.41--135.44---40.39-11.245.86--5.07--
Maat Pharma SA2.23m-19.72m109.19m50.00--5.34--49.01-1.73-1.730.1961.760.05084.844.1644,560.00-44.99-35.49-58.93-42.9874.28---884.96-1,157.542.76-49.610.4075--55.80---43.78--30.30--
Eurofins-Cerep SA46.17m9.21m109.96m233.0011.941.839.822.381,826.411,826.419,160.0011,939.290.68141.666.04220,892.0013.6015.1916.0618.9485.5767.3019.9519.725.17112.420.000050.0014.4514.3017.0924.52----
DBV Technologies SA4.88m-94.22m114.98m88.00--0.7503--23.55-1.00-1.000.05181.590.0209--0.373870,752.81-40.35-64.67-46.22-80.94--91.59-1,929.97-1,345.10----0.0128---15.14-18.452.08---38.41--
Adocia SA5.73m-20.55m121.96m100.00------21.30-2.36-2.360.6532-1.900.1823--16.7955,048.08-65.43-25.65-341.43-37.22-----358.85-101.110.5924-2.782.81--692.73-10.0869.67---40.08--
Transgene SA7.63m-22.33m125.46m158.00--8.01--16.43-0.2227-0.22270.07590.15530.1368--4.2848,316.46-40.00-24.81-50.27-29.79-----292.48-193.24----0.4764---23.681.5131.94--14.44--
Ose Immunotherapeutics SA2.23m-23.00m134.96m62.00--5.82--60.60-1.18-1.180.11661.060.0256--3.22---26.46-17.17-33.15-20.55-----1,032.87-94.71---97.810.6659---87.83-38.07-29.52---17.11--
Eurobio Scientific SA130.00m4.84m148.61m137.0033.610.9056.391.140.43150.431511.5916.020.40183.194.31948,927.001.4916.911.8021.5347.1150.953.7223.342.322.810.36660.00-14.8120.80-80.61--20.02--
Genfit SA38.18m-28.89m161.22m159.00--2.37--4.22-0.5814-0.58140.76811.360.1961542.003.52240,100.60-14.84-12.57-18.55-15.3094.3294.96-75.69-76.232.94-7.780.5080--43.7038.49-21.82---3.27--
Inventiva SA17.48m-110.43m165.83m112.00------9.49-2.45-2.450.3854-0.61460.1884--9.18156,044.60-116.84-54.30-207.08-69.98-----620.31-669.970.9524-19.986.96--43.5040.46-103.46---0.33--
Aelis Farma SA9.05m-5.08m172.35m26.00--13.06--19.04-0.3907-0.39070.70190.99570.2765--2.41348,230.80-15.51-24.53-25.59-40.55-----56.09-109.622.47--0.1547--137.70--64.46--37.35--
Innate Pharma SA51.90m-7.57m178.30m179.00--3.43--3.44-0.0939-0.09390.64510.6420.2648--5.67289,949.70-3.86-8.83-4.87-12.1194.5093.17-14.59-55.55----0.6408--4.68-8.2786.94--10.50--
Cellectis SA8.55m-101.74m197.43m235.00--2.51--23.10-1.74-1.630.15461.100.0309--13.7136,362.81-39.24-24.08-60.81-30.69---64.64-1,270.92-308.24---5.080.5429---64.26-15.57-20.55---26.15--
Sensorion SA0.00-22.06m210.78m50.00--3.95-----0.2063-0.20630.000.17790.00-------51.64-35.12-71.66-46.97------------0.0794------4.94--126.45--
Data as of May 03 2024. Currency figures normalised to Inventiva SA's reporting currency: Euro EUR

Institutional shareholders

33.13%Per cent of shares held by top holders
HolderShares% Held
BVF Partners LPas of 01 Mar 20247.86m15.08%
Qatar Investment Authority (Investment Management)as of 01 Mar 20245.16m9.90%
Yiheng Capital Management LPas of 01 Mar 20243.85m7.38%
Amundi Asset Management SA (Investment Management)as of 29 Feb 2024186.58k0.36%
DNCA Finance SAas of 30 Jun 2021120.00k0.23%
UBS LA MAISON de Gestionas of 30 Dec 202237.50k0.07%
BG Fund Management Luxembourg SAas of 30 Jun 202329.78k0.06%
Financi�re Arbevel SAas of 30 Dec 202221.00k0.04%
Crossinvest SAas of 30 Jun 20237.49k0.01%
Gestys SAas of 26 Jan 20243.50k0.01%
More ▼
Data from 31 Oct 2023 - 24 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.